Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study

Radhika Gangaraju, Yanjun Chen, Lindsey Hageman, Jessica Wu, Liton Francisco, Kevin Battles, Michelle Kung, Emily Ness, Mariel Parman, Daniel J. Weisdorf, Stephen J. Forman, Mukta Arora, Saro H. Armenian, Smita Bhatia

Research output: Contribution to journalArticle

Abstract

Hemostatic complications are commonly encountered in blood or marrow transplantation (BMT) recipients, increasing their morbidity and mortality and are well described in the immediate post-transplantation period. The risk of venous thromboembolism (VTE) in long-term survivors of autologous BMT has not been studied previously. Patients who underwent autologous BMT between January 1, 1974, and December 31, 2010 for a hematologic malignancy, lived 2 years or more after transplantation, and were age ≥18 years were surveyed for long-term outcomes. The median duration of follow-up was 9.8 years (interquartile range, 6.4 to 14.3 years). We analyzed the risk of VTE in 820 autologous BMT recipients who survived for ≥2 years, compared with 644 siblings. BMT survivors were at a 2.6-fold higher risk of VTE compared with siblings (95% confidence interval [CI], 1.6 to 4.4; P =.0004), after adjusting for sociodemographic characteristics. Conditional on surviving for ≥2 years after BMT, the mean cumulative incidence of VTE was 3.9 ± .8% at 5 years and 6.1 ± 1.1% at 10 years. A diagnosis of plasma cell disorder (hazard ratio [HR], 2.37; 95% CI, 1.3 to 4.2; P = .004) and annual household income ≤$50,000 (HR, 2.02; 95% CI, 1.2 to 3.6; P = .015) were associated with increased VTE risk. Our data indicate that autologous BMT survivors are at elevated risk for developing late-occurring VTE. The development of risk prediction models to identify autologous BMT survivors at greatest risk for VTE and thromboprophylaxis may help decrease the morbidity and mortality associated with VTE.

Original languageEnglish (US)
Pages (from-to)2261-2266
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume25
Issue number11
DOIs
StatePublished - Nov 2019

Fingerprint

Venous Thromboembolism
Survivors
Transplantation
Bone Marrow
Transplants
Confidence Intervals
Siblings
Morbidity
Mortality
Hemostatics
Hematologic Neoplasms
Plasma Cells
Incidence

Keywords

  • Autologous BMT
  • BMT survivors
  • Plasma cell dyscrasia
  • Venous thromboembolism

PubMed: MeSH publication types

  • Journal Article

Cite this

Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors : A Report from the Blood or Marrow Transplant Survivor Study. / Gangaraju, Radhika; Chen, Yanjun; Hageman, Lindsey; Wu, Jessica; Francisco, Liton; Battles, Kevin; Kung, Michelle; Ness, Emily; Parman, Mariel; Weisdorf, Daniel J.; Forman, Stephen J.; Arora, Mukta; Armenian, Saro H.; Bhatia, Smita.

In: Biology of Blood and Marrow Transplantation, Vol. 25, No. 11, 11.2019, p. 2261-2266.

Research output: Contribution to journalArticle

Gangaraju, R, Chen, Y, Hageman, L, Wu, J, Francisco, L, Battles, K, Kung, M, Ness, E, Parman, M, Weisdorf, DJ, Forman, SJ, Arora, M, Armenian, SH & Bhatia, S 2019, 'Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study', Biology of Blood and Marrow Transplantation, vol. 25, no. 11, pp. 2261-2266. https://doi.org/10.1016/j.bbmt.2019.06.032
Gangaraju, Radhika ; Chen, Yanjun ; Hageman, Lindsey ; Wu, Jessica ; Francisco, Liton ; Battles, Kevin ; Kung, Michelle ; Ness, Emily ; Parman, Mariel ; Weisdorf, Daniel J. ; Forman, Stephen J. ; Arora, Mukta ; Armenian, Saro H. ; Bhatia, Smita. / Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors : A Report from the Blood or Marrow Transplant Survivor Study. In: Biology of Blood and Marrow Transplantation. 2019 ; Vol. 25, No. 11. pp. 2261-2266.
@article{202ff5989d00467cbf97ab72d2a24390,
title = "Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study",
abstract = "Hemostatic complications are commonly encountered in blood or marrow transplantation (BMT) recipients, increasing their morbidity and mortality and are well described in the immediate post-transplantation period. The risk of venous thromboembolism (VTE) in long-term survivors of autologous BMT has not been studied previously. Patients who underwent autologous BMT between January 1, 1974, and December 31, 2010 for a hematologic malignancy, lived 2 years or more after transplantation, and were age ≥18 years were surveyed for long-term outcomes. The median duration of follow-up was 9.8 years (interquartile range, 6.4 to 14.3 years). We analyzed the risk of VTE in 820 autologous BMT recipients who survived for ≥2 years, compared with 644 siblings. BMT survivors were at a 2.6-fold higher risk of VTE compared with siblings (95{\%} confidence interval [CI], 1.6 to 4.4; P =.0004), after adjusting for sociodemographic characteristics. Conditional on surviving for ≥2 years after BMT, the mean cumulative incidence of VTE was 3.9 ± .8{\%} at 5 years and 6.1 ± 1.1{\%} at 10 years. A diagnosis of plasma cell disorder (hazard ratio [HR], 2.37; 95{\%} CI, 1.3 to 4.2; P = .004) and annual household income ≤$50,000 (HR, 2.02; 95{\%} CI, 1.2 to 3.6; P = .015) were associated with increased VTE risk. Our data indicate that autologous BMT survivors are at elevated risk for developing late-occurring VTE. The development of risk prediction models to identify autologous BMT survivors at greatest risk for VTE and thromboprophylaxis may help decrease the morbidity and mortality associated with VTE.",
keywords = "Autologous BMT, BMT survivors, Plasma cell dyscrasia, Venous thromboembolism",
author = "Radhika Gangaraju and Yanjun Chen and Lindsey Hageman and Jessica Wu and Liton Francisco and Kevin Battles and Michelle Kung and Emily Ness and Mariel Parman and Weisdorf, {Daniel J.} and Forman, {Stephen J.} and Mukta Arora and Armenian, {Saro H.} and Smita Bhatia",
year = "2019",
month = "11",
doi = "10.1016/j.bbmt.2019.06.032",
language = "English (US)",
volume = "25",
pages = "2261--2266",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors

T2 - A Report from the Blood or Marrow Transplant Survivor Study

AU - Gangaraju, Radhika

AU - Chen, Yanjun

AU - Hageman, Lindsey

AU - Wu, Jessica

AU - Francisco, Liton

AU - Battles, Kevin

AU - Kung, Michelle

AU - Ness, Emily

AU - Parman, Mariel

AU - Weisdorf, Daniel J.

AU - Forman, Stephen J.

AU - Arora, Mukta

AU - Armenian, Saro H.

AU - Bhatia, Smita

PY - 2019/11

Y1 - 2019/11

N2 - Hemostatic complications are commonly encountered in blood or marrow transplantation (BMT) recipients, increasing their morbidity and mortality and are well described in the immediate post-transplantation period. The risk of venous thromboembolism (VTE) in long-term survivors of autologous BMT has not been studied previously. Patients who underwent autologous BMT between January 1, 1974, and December 31, 2010 for a hematologic malignancy, lived 2 years or more after transplantation, and were age ≥18 years were surveyed for long-term outcomes. The median duration of follow-up was 9.8 years (interquartile range, 6.4 to 14.3 years). We analyzed the risk of VTE in 820 autologous BMT recipients who survived for ≥2 years, compared with 644 siblings. BMT survivors were at a 2.6-fold higher risk of VTE compared with siblings (95% confidence interval [CI], 1.6 to 4.4; P =.0004), after adjusting for sociodemographic characteristics. Conditional on surviving for ≥2 years after BMT, the mean cumulative incidence of VTE was 3.9 ± .8% at 5 years and 6.1 ± 1.1% at 10 years. A diagnosis of plasma cell disorder (hazard ratio [HR], 2.37; 95% CI, 1.3 to 4.2; P = .004) and annual household income ≤$50,000 (HR, 2.02; 95% CI, 1.2 to 3.6; P = .015) were associated with increased VTE risk. Our data indicate that autologous BMT survivors are at elevated risk for developing late-occurring VTE. The development of risk prediction models to identify autologous BMT survivors at greatest risk for VTE and thromboprophylaxis may help decrease the morbidity and mortality associated with VTE.

AB - Hemostatic complications are commonly encountered in blood or marrow transplantation (BMT) recipients, increasing their morbidity and mortality and are well described in the immediate post-transplantation period. The risk of venous thromboembolism (VTE) in long-term survivors of autologous BMT has not been studied previously. Patients who underwent autologous BMT between January 1, 1974, and December 31, 2010 for a hematologic malignancy, lived 2 years or more after transplantation, and were age ≥18 years were surveyed for long-term outcomes. The median duration of follow-up was 9.8 years (interquartile range, 6.4 to 14.3 years). We analyzed the risk of VTE in 820 autologous BMT recipients who survived for ≥2 years, compared with 644 siblings. BMT survivors were at a 2.6-fold higher risk of VTE compared with siblings (95% confidence interval [CI], 1.6 to 4.4; P =.0004), after adjusting for sociodemographic characteristics. Conditional on surviving for ≥2 years after BMT, the mean cumulative incidence of VTE was 3.9 ± .8% at 5 years and 6.1 ± 1.1% at 10 years. A diagnosis of plasma cell disorder (hazard ratio [HR], 2.37; 95% CI, 1.3 to 4.2; P = .004) and annual household income ≤$50,000 (HR, 2.02; 95% CI, 1.2 to 3.6; P = .015) were associated with increased VTE risk. Our data indicate that autologous BMT survivors are at elevated risk for developing late-occurring VTE. The development of risk prediction models to identify autologous BMT survivors at greatest risk for VTE and thromboprophylaxis may help decrease the morbidity and mortality associated with VTE.

KW - Autologous BMT

KW - BMT survivors

KW - Plasma cell dyscrasia

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=85069842509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069842509&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2019.06.032

DO - 10.1016/j.bbmt.2019.06.032

M3 - Article

C2 - 31278995

AN - SCOPUS:85069842509

VL - 25

SP - 2261

EP - 2266

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 11

ER -